Supernus Pharmaceuticals(SUPN)（納斯達克股票代碼：SUPN）報告稱季度每股收益爲$0.27，與分析師普遍預期的$0.52相比低了48.08%。與去年同期的$0.39每股收益相比，下降了30.77%。公司報告季度銷售額爲$1.7416億，超出分析師普遍預期的$1.5525億，超出比例爲12.18%。與去年同期的$1.6431億銷售額相比，增長了5.99%。

以上內容來自Benzinga Earnings專欄，原文如下：

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.52 by 48.08 percent. This is a 30.77 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $174.16 million which beat the analyst consensus estimate of $155.25 million by 12.18 percent. This is a 5.99 percent increase over sales of $164.31 million the same period last year.